INTRODUCTION: Until the development of @entity734 ( @entity734 ), @entity256 (ISR) was the main limitation of bare-metal stents in percutaneous coronary intervention (PCI). Among the different treatments available, intracoronary brachytherapy (BT) emerged as one of the most promising, although it was almost abandoned with the increasing use of @entity734 . OBJECTIVE: To assess the Portuguese experience with 90Sr/90Y beta brachytherapy for the treatment of diffuse ISR regarding long-term (>10 years) major adverse @entity299 (MACE) and @entity256 . METHODS: This single-center, retrospective, observational study included 12 consecutive @entity1 treated between January and June 2001, mean age 58.6  9.9 years (range 43-77 years), 11 male. All had @entity5749 , 75% had @entity2299 , 58% had @entity101 , 50% had @entity3657 , 42% had @entity6 and 50% had multivessel disease. Recurrent ISR was present in half of the @entity1 and 11 had normal left ventricular function. After balloon dilatation, BT was performed using an Sr90/Y90 (Novoste Beta-CathTM) beta radiation source. All @entity1 remained under dual antiplatelet therapy until scheduled nine-month follow-up angiography. @entity1 were followed for the occurrence of @entity204 (all-cause and cardiovascular), non-fatal @entity583 ( @entity583 ), revascularization, stent @entity715 and @entity256 . MACE were defined as the combined incidence of @entity204 , @entity583 and urgent target vessel revascularization. RESULTS: In all cases there was both clinical and angiographic success. In a mean follow-up of 10.9  2.5 years, 19 events occurred in seven @entity1 : @entity204 in three (25%), only one cardiac (8.3%); ST-elevation @entity583 in one (related to a non-target vessel) (8.3%); and 15 revascularizations in five (42%), of which nine were of the target vessel (mainly in the first two years). There was only one case of probable stent @entity715 . Angiographic restenosis at nine months was 27% (three out of 11 @entity1 ), of which two were total occlusions. Ten-year MACE-free survival was 42% (5 @entity1 ). CONCLUSIONS: Intracoronary beta brachytherapy for the treatment of diffuse ISR in this small cohort of @entity1 proved to be safe and efficacious, with no late adverse events related to intracoronary radiation.

Late results (>10 years) of intracoronary beta brachytherapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity3657 :: ('MESH:D058729', 'Disease') :: ['peripheral arterial disease'] @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity5749 :: ('MESH:D060050', 'Disease') :: ['chronic stable angina'] @entity256 :: ('MESH:D023903', 'Disease') :: ['angiographic restenosis', 'diffuse in-stent restenosis'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI'] @entity204 :: ('MESH:D003643', 'Disease') :: ['cardiac death', 'death'] @entity734 :: ('MESH:D019966', 'Disease') :: ['DES', 'drug-eluting stents'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']
@entity256 :: (MESH:D023903,Disease) :: ['diffuse in-stent restenosis']
